In a regulatory filing, Immunome (IMNM) disclosed that its CTO Philip Tsai bought 12.3K shares of common stock on March 24th in a total transaction size of $103.6K. Shares are up 5% afterhours at $7.29.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome’s Promising Pipeline and Strategic Acquisition Drive Buy Rating
- Immunome’s Promising Pipeline and Strategic Advancements Support Buy Rating
- Immunome’s 2024 Financial Results and Pipeline Progress
- Immunome price target lowered to $25 from $35 at Guggenheim
- Immunome reports FY24 revenue $9.04M, consensus $9.41M